Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
| Autor: | Richard L. Weinberg, Kim A. Eagle, Robert D. Brook, Melvyn Rubenfire |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
chemistry.chemical_classification
Nutritional Supplementation business.industry Hypertriglyceridemia Physiology 030204 cardiovascular system & hematology medicine.disease Fish oil Eicosapentaenoic acid Clinical trial 03 medical and health sciences 0302 clinical medicine chemistry Docosahexaenoic acid Dietary Reference Intake medicine lipids (amino acids peptides and proteins) 030212 general & internal medicine Cardiology and Cardiovascular Medicine business Polyunsaturated fatty acid |
| Zdroj: | Journal of the American College of Cardiology. 77:593-608 |
| ISSN: | 0735-1097 |
| Popis: | Omega-3 polyunsaturated fatty acids (PUFAs) are a key component of a heart-healthy diet. For patients without clinical atherosclerotic cardiovascular disease, 2 or more servings of fatty fish per week is recommended to obtain adequate intake of omega-3 PUFAs. If this not possible, dietary supplementation with an appropriate fish oil may be reasonable. Supplementation with omega-3 PUFA capsules serves 2 distinct but overlapping roles: treatment of hypertriglyceridemia and prevention of cardiovascular events. Marine-derived omega-3 PUFAs reduce triglycerides and have pleiotropic effects including decreasing inflammation, improving plaque composition and stability, and altering cellular membranes. Clinical trial data have shown inconsistent results with omega-3 PUFAs improving cardiovascular outcomes. In this paper, the authors provide an overview of PUFAs and a summary of key clinical trial data. Recent trial data suggest the use of prescription eicosapentaenoic acid ethyl ester for atherosclerotic cardiovascular disease event reduction in selected populations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|